Turning Failure into Success: Trials of the Heart Failure Clinical Research Network

Curr Cardiol Rep. 2016 Dec;18(12):121. doi: 10.1007/s11886-016-0801-2.

Abstract

The Heart Failure Clinical Research Network (HFN) was established in 2008 on behalf of the NIH National Heart, Lung and Blood Institute, with the primary goal of improving outcomes in heart failure (HF) by designing and conducting high-quality concurrent clinical trials testing interventions across the spectrum of HF. Completed HFN trials have answered several important and relevant clinical questions concerning the safety and efficacy of different decongestive and adjunctive vasodilator therapies in hospitalized acute HF, phosphodiesterase-5 inhibition and nitrate therapies in HF with preserved ejection fraction, and the role of xanthine oxidase inhibition in hyperuricemic HF. These successes, independent of the "positive" or "negative" result of each individual trial, have helped to shape the current clinical care of HF patients and serve as a platform to inform future research directions and trial designs.

Keywords: Clinical research; Clinical trials; Heart failure.

Publication types

  • Review

MeSH terms

  • Diuretics / pharmacology
  • Double-Blind Method
  • Enzyme Inhibitors / pharmacology
  • Heart Failure / blood
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Humans
  • Nitrates / pharmacology
  • Phosphodiesterase 5 Inhibitors / pharmacology
  • Randomized Controlled Trials as Topic*
  • Translational Research, Biomedical*
  • Treatment Outcome
  • United States
  • Vasodilator Agents / pharmacology
  • Xanthine Oxidase / antagonists & inhibitors

Substances

  • Diuretics
  • Enzyme Inhibitors
  • Nitrates
  • Phosphodiesterase 5 Inhibitors
  • Vasodilator Agents
  • Xanthine Oxidase